In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vifor Pharma Group

www.viforpharma.com

Latest From Vifor Pharma Group

Deal Watch: Allergan Keeps After Hair Loss With Exicure Deal

Allergan has tried to go after alopecia in the past; Exicure brings a new spherical nucleic acid (SNA) technology. In other recent deals, AstraZeneca sells Seroquel, Losec rights to Germany’s Cheplapharm.

Deals Business Strategies

Evotec, Vifor JV To Fight Kidney Disease

Evotec’s CSO says its new joint venture with Vifor will use patient-driven data to identify and develop targeted therapies to treat kidney disease with.

Commercial Companies

Deal Watch: Gilead Hopes Glympse’s Synthetic Biomarkers Can Optimize NASH Trials

Gilead partners with Glympse to optimize NASH trials, while Ironwood will work with Pear on digital therapies for GI disorders. An alliance between Leo and Ubiquigent yields an option agreement around two novel compounds.

Deals Business Strategies

Vifor Boosts US Nephrology Prospects With Janssen Pact

Vifor has boosted its US nephrology prospects with a pact with Janssen to jointly market Invokana in diabetic kidney disease.

Deals Companies
See All

Company Information

UsernamePublicRestriction

Register